The present invention provides an orally administrable pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation, wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is intranasally administered in physically compromised form to a subject, the Cmax and/or AUG of the drug achieved after a time period is lower than the Cmax and/or AUG of the drug achieved after intranasal administration of a physically compromised form of an orally bioequivalent composition not containing one or more pharmaceutically acceptable excipients in an amount sufficient to deter abuse by nasal insufflation.
